- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 16
The Center for Biosimilars® recaps the top stories for the week of September 16, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 16, 2019.
Number 5: Innovator drug maker Roche says that it plans to see substantial erosion of its sales of rituximab, trastuzumab, and bevacizumab products by 2023.
Number 4: The American College of Rheumatology says that a large proportion of patients with rheumatic diseases had difficulty accessing and paying for their therapies in the past year.
Number 3: The Biosimilars Council has issued part 2 of its recent white paper on barriers to biosimilars in the United States; the newly published segment highlights post-market challenges to biosimilar adoption.
Number 2: A recent study says that step therapy in rheumatoid arthritis or psoriatic arthritis can hurt treatment outcomes.
Number 1: The United States Court of Appeals for the Third Circuit sided with Johnson & Johnson, requiring a dispute between the drug maker and Rochester Drug Cooperative to be sent to arbitration.
Finally, last week, our e-newsletter asked whether you think that Europe’s biosimilars market faces challenges to sustainability.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
